← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

Lin Patrick

Chief Business - Strategy Off

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001799363

Purchase history

Companies traded
1
Purchases · 12M
6
Purchases · 24M
7
Average purchase
$8.5K
Median purchase
$4.1K
Gross purchase value
$59.2K

Companies: Processa Pharmaceuticals, Inc.

7 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-07-01Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$4.1KOpen filing
2026-06-16Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$4.1KOpen filing
2026-06-01Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$4.1KOpen filing
2026-05-19Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$4.1KOpen filing
2026-05-01Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$4.1KOpen filing
2026-04-17Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$4.1KOpen filing
2025-01-29Processa Pharmaceuticals, Inc.PCSAChief Business - Strategy Off$34.8KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

PeriodCompleted eventsPrice coverageHit rateMedian excess returnAverage excess returnWorst excess return
5D7Developing100.0% (7/7)28.6% (2/7)-1.8%-2.5%-10.7%
20D7Developing100.0% (7/7)28.6% (2/7)-6.2%-7.2%-22.8%
60D7Developing100.0% (7/7)0.0% (0/7)-17.1%-20.8%-51.7%
120D2Small Sample100.0% (2/2)0.0% (0/2)-65.6%-65.6%-66.0%

Research patterns

First purchase in 12M
1/6
Large purchase ≥ $100k
0/7
Cluster buying · 15D
7/7
Buying the dip
7/7

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.